Abstract
From its discovery as an adaptive bacterial and archaea immune system, the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas system has quickly been developed into a powerful and groundbreaking programmable nuclease technology for the global and precise editing of the genome in cells. This system allows for comprehensive unbiased functional studies and is already advancing the field by revealing genes that have previously unknown roles in disease processes. In this review, we examine and compare recently developed CRISPR-Cas platforms for global genome editing and examine the advancements these platforms have made in guide RNA design, guide RNA/Cas9 interaction, on-target specificity, and target sequence selection. We also explore some of the exciting therapeutic potentials of the CRISPR-Cas technology as well as some of the innovative new uses of this technology beyond genome editing.
Date of this Version
2015
DOI
10.1186/s13045-015-0127-3
Recommended Citation
Sean E Humphrey and Andrea L Kasinski. RNA-guided CRISPR-Cas technologies for genome-scale investigation of disease processes. Journal of Hematology & Oncology 2015. 8:31 DOI: 10.1186/s13045-015-0127-3
Comments
Sean E Humphrey and Andrea L Kasinski. RNA-guided CRISPR-Cas technologies for genome-scale investigation of disease processes. Journal of Hematology & Oncology 2015. 8:31 DOI: 10.1186/s13045-015-0127-3
(CC BY 4.0)